- South Korea
- /
- Pharma
- /
- KOSE:A326030
Asian Companies Estimated Below Fair Value In October 2025
Reviewed by Simply Wall St
In October 2025, Asian markets are navigating a complex landscape marked by mixed economic signals and evolving monetary policies. As investors seek opportunities in this environment, identifying stocks that appear undervalued can be a strategic approach to potentially capitalize on market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
Name | Current Price | Fair Value (Est) | Discount (Est) |
Xiamen Amoytop Biotech (SHSE:688278) | CN¥84.05 | CN¥165.09 | 49.1% |
Tibet GaoZheng Explosive (SZSE:002827) | CN¥38.57 | CN¥76.72 | 49.7% |
Takara Bio (TSE:4974) | ¥953.00 | ¥1829.46 | 47.9% |
Samyang Foods (KOSE:A003230) | ₩1509000.00 | ₩3006664.22 | 49.8% |
Malee Group (SET:MALEE) | THB5.60 | THB11.01 | 49.1% |
freee K.K (TSE:4478) | ¥3270.00 | ¥6517.32 | 49.8% |
Devsisters (KOSDAQ:A194480) | ₩48200.00 | ₩95922.40 | 49.8% |
Dajin Heavy IndustryLtd (SZSE:002487) | CN¥47.21 | CN¥90.85 | 48% |
Com2uS (KOSDAQ:A078340) | ₩36500.00 | ₩70061.62 | 47.9% |
Aecc Aero Science and TechnologyLtd (SHSE:600391) | CN¥28.43 | CN¥54.77 | 48.1% |
Let's review some notable picks from our screened stocks.
SK Biopharmaceuticals (KOSE:A326030)
Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩8.14 trillion.
Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, amounting to ₩620.28 million.
Estimated Discount To Fair Value: 45.2%
SK Biopharmaceuticals is trading at ₩104,000, significantly below its estimated fair value of ₩189,933.83. Despite earnings growth being slower than the market average, revenue is expected to grow 23.4% annually—outpacing the KR market's 7.6%. The stock is undervalued by over 20%, and its Return on Equity is projected to reach a robust 30.5% in three years, indicating strong future profitability potential despite high non-cash earnings levels.
- According our earnings growth report, there's an indication that SK Biopharmaceuticals might be ready to expand.
- Click here and access our complete balance sheet health report to understand the dynamics of SK Biopharmaceuticals.
Tianqi Lithium (SZSE:002466)
Overview: Tianqi Lithium Corporation engages in the investment, production, processing, extraction, and sale of lithium and lithium compounds across Australia, Chile, and China with a market capitalization of approximately CN¥77.75 billion.
Operations: Tianqi Lithium generates revenue through the investment, production, processing, extraction, and sale of lithium products and compounds in Australia, Chile, and China.
Estimated Discount To Fair Value: 41.6%
Tianqi Lithium is trading at CN¥47.57, significantly below its estimated fair value of CN¥81.48, suggesting it may be undervalued based on cash flows. Despite a decline in sales to CN¥4.82 billion for H1 2025 from CN¥6.42 billion a year ago, the company turned profitable with net income of CN¥84.41 million compared to a significant loss previously. Revenue is forecasted to grow 16.1% annually, surpassing the broader Chinese market's growth rate.
- Insights from our recent growth report point to a promising forecast for Tianqi Lithium's business outlook.
- Get an in-depth perspective on Tianqi Lithium's balance sheet by reading our health report here.
Wiwynn (TWSE:6669)
Overview: Wiwynn Corporation is involved in the research, development, design, testing, and sales of semiconductor products and peripheral equipment globally, with a market cap of NT$643.94 billion.
Operations: The company's revenue is primarily derived from its Computer Hardware segment, totaling NT$604.83 billion.
Estimated Discount To Fair Value: 12.3%
Wiwynn, trading at NT$3465, is below its estimated fair value of NT$3952.5, potentially indicating undervaluation based on cash flows. Recent earnings show significant growth with Q2 sales reaching NT$220.74 billion from NT$77.48 billion a year ago and net income rising to NT$12.12 billion from NT$4.69 billion previously. Despite high revenue growth forecasts of 23.8% annually, earnings are expected to grow slower than the Taiwan market average at 13.3%.
- In light of our recent growth report, it seems possible that Wiwynn's financial performance will exceed current levels.
- Navigate through the intricacies of Wiwynn with our comprehensive financial health report here.
Turning Ideas Into Actions
- Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 279 companies by clicking here.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSE:A326030
SK Biopharmaceuticals
A pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders.
Flawless balance sheet with high growth potential.
Market Insights
Community Narratives


